Disease Domain | Count |
---|---|
Neoplasms | 2 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Unknown | 1 |
Bispecific antibody | 1 |
Small molecule drug | 1 |
Target |
Mechanism Bcl-xl inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PfPMX inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BAK inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator ![]() [+4] |
Start Date11 Oct 2022 |
Sponsor / Collaborator |
Start Date20 May 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
WEHI-539 ( Bcl-xl ) | Solid tumor More | Preclinical |
WM-382 ( PfPMX ) | Plasmodium knowlesi infection More | Preclinical |
7D10-PAT-DX1 ( BAK x DNA ) | Breast Cancer More | Discovery |
Emfilermin ( LIF ) | Neuromuscular Diseases More | Discontinued |
WEHI-345 | Multiple Sclerosis More | Pending |